🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thrilled to share our new analysis from CheckMate 901! 🟡In N+ only metastatic UC, Nivolumab + chemo doubled complete response rate vs chemo alone (63% vs 34%) and prolonged PFS (HR 0.38) and OS (HR 0.58). ➡️A new horizon for a distinct subgroup. European Urology OncoAlert

Was a great meeting and very productive to further explore NECTIN4 amplification for precision oncology Bicycle Therapeutics Markus Eckstein Johannes Brägelmann UroToday.com OncoAlert

What a fantastic and intense meeting with Bicycle Therapeutics in Cambridge !exciting journey to travel on the nectin4 amplification road! Niklas Klümper #precision oncology

Great overview by Raffaele Colombo ! ADCs and small peptides are so exciting - they are and will be the key for future precision oncology UroToday.com OncoAlert Niklas Klümper

Great editorial on Very High-risk NMIBC with real-world data challenging current guidelines on upfront radical cystectomy. Current progress in BCG-naïve NMIBC might enable bladder-preservation in more patients: CREST (BCG+sasanlimab), ALBAN (BCG+atezolizumab), POTOMAC

Ever wondered how to cost effectively implement molecular subtyping of muscle invasive #bladder #cancer ? We just published a publicly available pipeline relying on NextFlow and Quantseq to assign molecular consensus subtype in large scale! Costs per sample <200 💵!!!!! ➡️ ready

Ab#4501 ASCO #ASCO25 by @Jcensits Marinos Tsiatas👉bit.ly/44SqITu👉Ave+SG vs Ave as 1L maintenance in pts w/ aUC #bladdercancer👉Median PFS improved w/ combo (11.2 vs 3.8 mo)👇#BegonaValderrama OncoAlert UroToday.com Uromigos Bladder Cancer Advocacy Network

🚨 New preprint drop! MOSAIC builds a pan-cancer spatial + single-cell multi-omics atlas of thousands of tumors, exposing the fine-grained mosaic of intra-tumoral heterogeneity and immune niches. A game-changer for #PrecisionOncology and data-hungry AI models. More to come (much

📍Now it's time to highlight those abstracts that we'll see at #ASCO25 in kidney & bladder confirming their value as standard of care: 🏹1. #CHECKMATE-214: Among those patients who responded to Nivo-Ipi (42%) with 1L I/P prognosis, the possibilities to maintain the response

ASCO25 Zelenectide vedotin (BT8009) + pembro: ORR 65% (25% CR) in 1L cis-ineligible la/mUC (incl. PS 2). 👉#bicycle toxin conjugate (small peptide) targeting Nectin-4, with renal clearance (vs hepatic for EV). 👆Encouraging tolerability Matt Galsky Ignacio Duran Andrea Necchi

#ASCO25 Zelenectide vs EV: a small peptide (Zele) with same payload & target as EV, but faster renal clearance. 💥A new twist in Nectin-4 targeting for UC. Matt Galsky Ignacio Duran Andrea Necchi

🧬 Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC): • Most common mutations: TP53, TERT, ARID1A, ERBB2 • ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F) • Only ERBB2 amplifications associated with:

Beyond excited to present the results of our investigator-initiated #CLONEVO trial at #ASCO25 ASCO! 🏢Arie Crown Theater on May 31, 2025 🕐 Only 4 weeks of pre-op abemaciclib in patients with cisplatin-ineligible MIBC resulted in: ✅ 31% pathologic downstaging ✅ Clear

Every year, the Njardarson's group (University of Arizona) compiles the top 200 brand drugs by sales. The 2024 list is now posted! For ADCs, 2023 vs 2024 ranks: Enhertu 65 ➡️ 51 Padcev >200 ➡️ 73 Kadcyla 67 ⬅️ 94 Trodelvy 162 ➡️146 Polivy 169 ➡️ 159 Total ~$13 billions!

ASCO 2025: Nectin-4–Based Drug Conjugates in First-Line Treatment of Cisplatin-Ineligible la/mUC with Immunotherapy - A side-by-side look of PDC and ADC drugs. Follow us for the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #Immunotherapy #ADCs #CancerResearch

Finished the #picklelball charity game with Robert Haddad against the greatest New England Patriots players Rob Gronkowski + Julian Edelman to benefit The Jimmy Fund Dana-Farber + #GronkFoundation. Now off to #ASCO2025 ASCO

This is what excites me. #PrecisionOncology agnostic of tissue type. We enrolled patients with a variety of cancers to this 1st AGNOSTIC PARP⛔️trial. Long journey. Finally over the finishing line. 🧬BRCA, PALB2, RAD, BARD, & more. 🔗meetings.asco.org/abstracts-pres… #ASCO25 OncoAlert

🚨 BREAKING: HARMONi Trial Results Ivonescimab + chemo delivers a significant PFS benefit in EGFR-mutant NSCLC after EGFR TKI failure! 📊 PFS HR: 0.52 (p < 0.00001) 🧬 OS trending positive: HR 0.79 (p = 0.057)- not mature. 🌍 Global study with 38% Western pts 🛡 Manageable

Different novel therapies in NMIBC are approved #ASCO Andrea Necchi Matt Galsky Most are being tested in BCG pretreated patients. All have activity & many have a favourite, but with small single arm trials no one knows which is best. Now there are choices we should randomise?

🚨 #ASCO25 Update 🚨 🧬 Sacituzumab govitecan (SG) + pembrolizumab vs 💉 Chemo + pembro in 1L PD-L1+ mTNBC 📊 ASCENT-04 / KEYNOTE-D19 results: 🕒 PFS: 11.2 vs 7.8 mo 📉 HR: 0.65 (95% CI: 0.51–0.84), P = .0009 🎯 ORR: 59.7% vs 53.2% ⏳ DOR: 16.5 vs 9.2 mo 📉 Discontinuation due to